Calithera Biosciences, Inc.

Informe acción OTCPK:CALA

Capitalización de mercado: US$37.0k

Salud financiera de hoja de balance de Calithera Biosciences

Salud financiera controles de criterios 0/6

Datos insuficientes para determinar la salud financiera de Calithera Biosciences

Información clave

n/a

Ratio deuda-patrimonio

n/a

Deuda

Ratio de cobertura de interesesn/a
Efectivon/a
Patrimonion/a
Total pasivon/a
Activos totalesn/a

Actualizaciones recientes sobre salud financiera

Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Invest In Growth?

Aug 17
Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Invest In Growth?

We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth Carefully

Dec 17
We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth Carefully

We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth Carefully

Aug 27
We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth Carefully

Recent updates

Calithera gains 16% as FDA awards Fast Track status for lung cancer candidate

Oct 03

Calithera rises 8% after HC Wainwright upgrades rating to buy

Aug 29

Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Invest In Growth?

Aug 17
Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Invest In Growth?

We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth Carefully

Dec 17
We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth Carefully

We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth Carefully

Aug 27
We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth Carefully

The Upcoming Calithera Cystic Fibrosis Data Could Be Significant

Aug 03

Calithera Biosciences Investor Presentation - Slideshow

May 08

Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Deliver On Growth Plans?

May 02
Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Deliver On Growth Plans?

What Kind Of Investors Own Most Of Calithera Biosciences, Inc. (NASDAQ:CALA)?

Mar 10
What Kind Of Investors Own Most Of Calithera Biosciences, Inc. (NASDAQ:CALA)?

Calithera Biosciences, Inc. (NASDAQ:CALA) Shares Could Be 46% Below Their Intrinsic Value Estimate

Jan 17
Calithera Biosciences, Inc. (NASDAQ:CALA) Shares Could Be 46% Below Their Intrinsic Value Estimate

Calithera sinks as telaglenastat fails in kidney cancer study; lowers headcount

Jan 04

Companies Like Calithera Biosciences (NASDAQ:CALA) Are In A Position To Invest In Growth

Dec 13
Companies Like Calithera Biosciences (NASDAQ:CALA) Are In A Position To Invest In Growth

Calithera Biosciences Poised For Long-Term Success

Nov 25

Calithera Biosciences (CALA) Investor Presentation - Slideshow

Nov 06

Análisis de la situación financiera

Pasivos a corto plazo: Datos insuficientes para determinar si los activos a corto plazo de CALA cubren sus pasivos a corto plazo.

Pasivo a largo plazo: Datos insuficientes para determinar si los activos a corto plazo de CALA cubren sus pasivos a largo plazo.


Historial y análisis de deuda-patrimonio

Nivel de deuda: Datos insuficientes para calcular el ratio deuda neta-patrimonio de CALA para determinar si es satisfactorio.

Reducción de la deuda: No se dispone de datos suficientes para determinar si el ratio deuda-patrimonio de CALA se ha reducido en los últimos 5 años.

Cobertura de la deuda: Datos insuficientes para determinar si la deuda de CALA está bien cubierta por el flujo de caja operativo.

Cobertura de intereses: Datos insuficientes para determinar si los pagos de intereses de CALA sobre su deuda están bien cubiertos por el EBIT.


Hoja de balance


Descubre empresas con salud financiera